Arkansas Childrens

Little Rock, Arkansas 72202

6 studies enrolling now · 17 studies all time

What they study most

Amblyopia, B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia, B-Cell Lymphoblastic Leukemia, B-Cell Lymphoblastic Leukemia/Lymphoma, B-cell Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Leukemia, Duchenne Muscular Dystrophy, Exon 44, Exotropia Intermittent

Studies at this site

• Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy — Recruiting now
• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis — Recruiting now
• A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab — Recruiting now
• Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age — Recruiting now
• Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age — Recruiting now
• Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 — Recruiting now
• Full-Time Occlusion Therapy for Intermittent Exotropia in Children — Completed
• Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy — Running, not enrolling
• Trial of Overminus Spectacle Therapy for Intermittent Exotropia — Completed
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice — Running, not enrolling
• Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping — Completed
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) — Completed
• Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) — Stopped early
• Base-in Prism Spectacles for Intermittent Exotropia — Completed
• Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans — Completed